SERPING1 and hereditary angioedema: C1‐INH or icatibant are recommended for the treatment of HAE attacks in patients <12 years of age.When C1‐INH and icatibant are not available, SDP and FFP are second‐line therapies, with SDP preferred over FFP.Ecallantide is licensed for adolescents in the United States.